

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

WM3629

RRID:CVCL_C275

Type: Cell Line

Proper Citation

RRID:CVCL_C275

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C275

Proper Citation: RRID:CVCL_C275

Description: Cell line WM3629 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Melanoma

Defining Citation: [PMID:28196595](#)

Comments: Part of: Wistar Institute melanoma cell line collection., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: WM3629

Synonyms: WM-3629, WM 3629, WC00117, WC00117A

Cross References: cancercellines:CVCL_C275, Coriell:WC00117, Cosmic:1812179, Rockland:WM3629-01-0001, Wikidata:Q54994273

ID: CVCL_C275

Record Creation Time: 20220427T221721+0000

Record Last Update: 20260905T182756+0000

Ratings and Alerts

No rating or validation information has been found for WM3629.

Warning: Discontinued: Coriell; WC00117

Part of: Wistar Institute melanoma cell line collection., Part of: MD Anderson Cell Lines Project.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Rajkumar S, et al. (2022) Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell reports, 39(1), 110634.

Gong YY, et al. (2022) Na⁺/H⁺-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells. Cancer research communications, 2(8), 842.

Nguyen TT, et al. (2021) Mutations in the IFN γ -JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3432.

Molnár E, et al. (2018) Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. BMC cancer, 18(1), 542.